GGHC
SLNO

Gilder Gagnon Howe & Co’s Soleno Therapeutics SLNO Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,086
Closed -$2.36M – 254
2025
Q1 		$2.36M Buy
+33,086
New +$1.61M 0.03% 163

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Gilder Gagnon Howe & Co's SLNO Position: Q2 2025 in Review

Gilder Gagnon Howe & Co sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 33,086 shares — an estimated $2.36M sold.

Gilder Gagnon Howe & Co first reported a position in SLNO in Q1 2025 and held it in 1 quarter. The position peaked at $2.36M in Q1 2025. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

  • Gilder Gagnon Howe & Co reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 33,086 Soleno Therapeutics shares in Q2 2025, an estimated $2.36M.
  • Gilder Gagnon Howe & Co first reported a position in Soleno Therapeutics in Q1 2025 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Soleno Therapeutics position peaked at $2.36M in Q1 2025.
  • 233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2025, filed 14 Aug 2025.